venetoclax,acalabrutinib,obinutuzumab
astrazeneca,abbvie,roche
['cll', 'obinu', 'venetoclax', 'acalabrutinib', 'leukemia']
dana-farber s, christine ryan, m.d. presented her findings at #ash22, which showed a triple regimen of avo was highly effective in patients with high-risk forms of chronic lymphocytic leukemia. 
Dana-Farber Cancer Institute - a leading center for expert, compassionate cancer care and advanced research.
Appts: 877-442-3324 | https://t.co/HvCwkLltic